Anlon Healthcare Limited — Q1FY27 earnings call summary

Filed 12 August 2026 · Official transcript

Expect EBITDA margin normalization to 25-30% range by Q2/Q3 FY27 as raw material prices stabilize
Capacity expanded to 1400-1600 MT; utilization ~65-70%; new 1200 MT capacity commissioning expected Q1 FY28
Q1 FY27 consolidated revenue 87.62 Cr (+163% y-y), EBITDA 15.65 Cr, PAT 8.28 Cr
Consolidated EBITDA margin expected 25-27% for FY27; PAT margin guidance 12-13%
EBITDA margin moderated to ~17% due to raw material price surge and consolidation of Remember India Health Links
FY27 revenue guidance raised to 350-400 Cr, driven by organic growth and acquisitions
Mid-term target: ~30% revenue CAGR over next 3 years with integrated pharma platform
Working capital days ~170-180; positive operating cash flow expected by FY27 end